CITIC Securities: Maintains "Buy" rating on Henlius (02696.HK), target price HK$122

Zhitong Finance APP has learned that CITIC Securities has issued a research report stating that in the context of biosimilars going global, Henlius Biotech's (02696.HK) global value is highlighted, and the company's second growth curve in innovative drugs is clear, with abundant catalysts from blockbuster products and early-stage pipelines. Using a DCF model, the bank estimates Henlius Biotech's reasonable equity value at HK$66.7 billion, corresponding to a target price of HK$122 for 2026, and maintains a "Buy" rating.